The firm is seeking to expand the indication for its siRNA drug, which is already approved for familial chylomicronemia syndrome.
NEW YORK – Abbisko Therapeutics has begun treating cancer patients harboring KRAS alterations with the pan-KRAS Inhibitor ABSK211 in a Phase I trial.
The company said it will use the funds raised from sales of convertible notes to fund its oncology business, including intismeran autogene.
In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...
NEW YORK –Ideaya Biosciences and Genentech on Wednesday said they will study Ideaya's PRMT5 inhibitor IDE892 with Genentech's KRAS G12D inhibitor GDC-7035 in patients with pancreatic cancer. The trial ...
BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...
Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...
NEW YORK – Adaptin Bio is launching a Phase I trial of a T-cell engager in patients with malignant brain tumors harboring EGFR variant III mutations. The 15-patient study — the company's first — will ...
NEW YORK – An analysis of Medicare claims data over seven years found that uptake of next-generation sequencing in cancer was slower than expected after Medicare began covering testing. The research, ...
University of Toronto researchers are betting yes, pointing to tRNA's ease of administration and efficacy advantages over ...
The hospital, which has been making investments into precision medicine, inked a multi-phase deal to integrate PGx into clinical workflows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results